Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FABP6 | P51161 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL969793 | 1.00 | TSHR (0.47) | TSHRALDH1A1MAPK1CYP2C19GAA | |
| SCHEMBL14136794 | 1.00 | TSHR (0.47) | TSHRALDH1A1MAPK1CYP2C19GAA | |
| Hydrochloric Acid SCHEMBL928631 | 0.98 | TSHR (0.46) | TSHRALDH1A1MAPK1CYP2C19GAA | |
| SCHEMBL67599 | 0.87 | TP53 (0.41) | TSHRALDH1A1MAPK1CYP2C19GAA | |
| SCHEMBL2686070 | 0.87 | TP53 (0.41) | TSHRALDH1A1MAPK1CYP2C19GAA | |
| SCHEMBL1812329 | 0.87 | TP53 (0.41) | TSHRALDH1A1MAPK1CYP2C19GAA | |
| Hydrochloric Acid SCHEMBL28583358 | 0.85 | TP53 (0.40) | TSHRALDH1A1MAPK1CYP2C19GAA | |
| Hydrochloric Acid SCHEMBL384129 | 0.85 | TP53 (0.40) | TSHRALDH1A1MAPK1CYP2C19GAA | |
| Hydrochloric Acid SCHEMBL928017 | 0.85 | TP53 (0.40) | TSHRALDH1A1MAPK1CYP2C19GAA | |
| SCHEMBL17804391 | 0.83 | TP53 (0.43) | TSHRALDH1A1MAPK1CYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329699-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | claimed |
| EP-2475667-A1 | INHIBITORS OF JAK | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | claimed |
| WO-2011029804-A1 | INHIBITORS OF JAK | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | claimed |
| CN-111094265-B | Pyrazole derivative compound and use thereof | 韩美药品株式会社 | 2023-07-25 | — | — | CN | disclosed |
| CN-114340634-A | Heterocyclic compounds as kinase inhibitors | 诺维逊生物股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11236122-B2 | Triterpene amine derivatives | DFH THERAPEUTICS (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-08-19 | — | — | US | disclosed |
| WO-2021003314-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| CN-111094265-A | Pyrazole derivative compound and use thereof | 韩美药品株式会社 | 2020-05-01 | — | — | CN | disclosed |
| US-8329699-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | disclosed |
| WO-2011029804-A1 | INHIBITORS OF JAK | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110059118-A1 | INHIBITORS OF JAK | DE VICENTE FIDALGO JAVIER | 2011-03-10 | — | — | US | disclosed |
| US-20110059118-A1 | INHIBITORS OF JAK | DE VICENTE FIDALGO JAVIER | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | BET1, PGGT1B, NFATC1 | TSHR 4117/4885ALDH1A1 3332/4885MAPK1 1527/4885 |
| US-20110059118-A1 | INHIBITORS OF JAK | JAK1, JAK3, JAK2 | TSHR 974/4885ALDH1A1 4659/4885MAPK1 261/4885 |
| US-11236122-B2 | Triterpene amine derivatives | BET1, PGGT1B, NFATC1 | TSHR 4117/4885ALDH1A1 3332/4885MAPK1 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.